Erin Wilson
Stock Analyst at Morgan Stanley
(1.81)
# 3,064
Out of 4,735 analysts
19
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $46 | $39.54 | +16.34% | 4 | Jul 10, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $228.00 | +221.05% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $169.81 | +126.72% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $205.69 | +28.83% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $347.52 | -41.01% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $205.07 | +21.91% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $12.04 | +215.61% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $17.63 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher | Initiates: Neutral | $341 | $573.06 | -40.49% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.73 | +3,030.07% | 4 | Nov 14, 2017 |
Rapid7
Jul 10, 2024
Maintains: Equal-Weight
Price Target: $46
Current: $39.54
Upside: +16.34%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $228.00
Upside: +221.05%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $169.81
Upside: +126.72%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $205.69
Upside: +28.83%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $347.52
Upside: -41.01%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $205.07
Upside: +21.91%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $12.04
Upside: +215.61%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $17.63
Upside: -
Thermo Fisher
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $573.06
Upside: -40.49%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.73
Upside: +3,030.07%